Esophageal cancer is one of the most common digestive cancers in the world.
Because of the limitation and resistence of the traditional chemotherapy drugs, it is important to explore new therapeutic targets and strategies for this refractory cancer.
Recently, targeting deubiquitinases has emerged as a promising avenue for the development of anti-tumor drugs.
However, the role and underlying mechanism of NSC632839, a broad-spectrum deubiquitinases inhibitor, in esophageal squamous cell carcinoma in vitro remain elusive.
